Stock Pulse
IDEXX Laboratories (IDXX) anticipates strong Q1 2025 results with projected earnings growth of 4.3% and revenue growth of 5.8%, driven by instrument installations and customer gains [1]. A positive Earnings Surprise Prediction (ESP) of 17.46% suggests the company may outperform expectations [8], [9], supported by recent positive earnings surprises and upward revisions to consensus EPS estimates [1], [9]. Despite recent market volatility and a 15.4% stock decline over the past four weeks [1], [3], analysts project long-term annual revenue and earnings growth for 2025 [2], [3], and the company's innovative new diagnostic tools and upcoming cancer diagnostics solution are expected to further strengthen its market position [5], [6]. While a large investor recently sold their IDXX holdings due to short-term revenue concerns [4], the company's substantial recurring revenue and strong growth potential suggest long-term opportunity [6]. IDXX will release Q1 2025 results on May 1st [7].